Page 5 - மென்ஸீஸ் ஆரோக்கியம் நிறுவனம் குயின்ஸ்லாந்து News Today : Breaking News, Live Updates & Top Stories | Vimarsana

South African variant yet more concerning Study on AstraZeneca vaccine’s efficacy against B.1.351 shows “disappointing” results. Geoff Caddick / AFP / Getty Images Early in February, the South African government suspended the AstraZeneca vaccine rollout after a small-scale trial found that the vaccine’s efficacy against the coronavirus variant (B.1.351) first identified in South Africa was highly reduced. Now, a new study, published today in  NEJM, found that the AstraZeneca vaccine might offer as little as 10% protection from developing mild to moderate COVID-19 infection caused by the South African variant. Scientists conducted a double-blind, placebo-controlled trial across multiple hospitals in South Africa to assess the AstraZeneca vaccine’s efficacy. Participants were randomly divided into two groups and administered two doses of either the vaccine or placebo.

South africaUnited kingdomSouth africanAdam taylorMenzies health institute queensland at griffith universityMenzies health institute queenslandஒன்றுபட்டது கிஂக்டம்பண்படாமனித இயல்பு டெய்லர்மென்ஸீஸ் ஆரோக்கியம் நிறுவனம் குயின்ஸ்லாந்து இல் கிரிஃபித் பல்கலைக்கழகம்மென்ஸீஸ் ஆரோக்கியம் நிறுவனம் குயின்ஸ்லாந்து